Experienced in Acute Lymphoblastic Leukemia (ALL)
Experienced in Acute Lymphoblastic Leukemia (ALL)
759 Chestnut Street, Sw3500, 
Springfield, MA 

Overview

Joanna Luty is a Pediatric Hematologist Oncology provider in Springfield, Massachusetts. Dr. Luty is rated as an Experienced provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Sickle Cell Disease, Evans Syndrome, and Leukemia.

Her clinical research consists of co-authoring 1 peer reviewed article and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 4 clinical trials in the study of Acute Lymphoblastic Leukemia (ALL).

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in MA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health New England
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Highmark
  • EPO
  • HMO
  • PPO
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 6 Less Insurance Carriers -

Locations

759 Chestnut Street, Sw3500, Springfield, MA 01107

Additional Areas of Focus

Dr. Luty has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


14 Clinical Trials

Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
View 13 Less Clinical Trials
Similar Doctors
Distinguished in Acute Lymphoblastic Leukemia (ALL)
Pediatric Hematology Oncology
Distinguished in Acute Lymphoblastic Leukemia (ALL)
Pediatric Hematology Oncology
20 York St, Ynhh (children's) West Pavilion - 2nd Floor, 
New Haven, CT 
 (58.9 miles away)
Languages Spoken:
English

Nina Kadan is a Pediatric Hematologist Oncology provider in New Haven, Connecticut. Dr. Kadan is rated as a Distinguished provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Hepatoblastoma, Langerhans Cell Histiocytosis, and Bone Marrow Aspiration.

Advanced in Acute Lymphoblastic Leukemia (ALL)
Pediatric Hematology Oncology
Advanced in Acute Lymphoblastic Leukemia (ALL)
Pediatric Hematology Oncology
800 Howard Ave, Yale Physicians Building, 
New Haven, CT 
 (59.1 miles away)
Languages Spoken:
English

Barbara Sleight is a Pediatric Hematologist Oncology provider in New Haven, Connecticut. Dr. Sleight is rated as an Advanced provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Hepatic Venoocclusive Disease with Immunodeficiency, and Immune Thrombocytopenic Purpura (ITP).

Advanced in Acute Lymphoblastic Leukemia (ALL)
Pediatric Hematology Oncology
Advanced in Acute Lymphoblastic Leukemia (ALL)
Pediatric Hematology Oncology
20 York St, 
New Haven, CT 
 (58.9 miles away)
Languages Spoken:
English

Kevin Mcnerney is a Pediatric Hematologist Oncology provider in New Haven, Connecticut. Dr. Mcnerney is rated as an Advanced provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). His top areas of expertise are Multisystem Inflammatory Syndrome in Children (MIS-C), Acute Lymphoblastic Leukemia (ALL), Neuroblastoma, Infantile Neutropenia, and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Luty's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile